首页> 美国卫生研究院文献>Marine Drugs >Marine-Derived Biologically Active Compounds for the Potential Treatment of Rheumatoid Arthritis
【2h】

Marine-Derived Biologically Active Compounds for the Potential Treatment of Rheumatoid Arthritis

机译:用于潜在治疗类风湿性关节炎的海洋衍生的生物活性化合物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease with a prevalence rate of up to 1% and is significantly considered a common worldwide public health concern. Commercially, several traditional formulations are available to treat RA to some extent. However, these synthetic compounds exert toxicity and considerable side effects even at lower therapeutic concentrations. Considering the above-mentioned critiques, research is underway around the world in finding and exploiting potential alternatives. For instance, marine-derived biologically active compounds have gained much interest and are thus being extensively utilized to confront the confines of in practice counterparts, which have become ineffective for 21st-century medical settings. The utilization of naturally available bioactive compounds and their derivatives can minimize these synthetic compounds’ problems to treat RA. Several marine-derived compounds exhibit anti-inflammatory and antioxidant properties and can be effectively used for therapeutic purposes against RA. The results of several studies ensured that the extraction of biologically active compounds from marine sources could provide a new and safe source for drug development against RA. Finally, current challenges, gaps, and future perspectives have been included in this review.
机译:类风湿性关节炎(RA)是一种慢性,全身自身免疫疾病,流行率高达1%,显着被认为是一个共同的全球公共卫生问题。商业上,可以在一定程度上进行几种传统配方可治疗RA。然而,即使在较低的治疗浓度下,这些合成化合物即使在较低的治疗浓度下也会施加毒性和相当大的副作用。考虑到上述批评,研究在世界各地寻找和利用潜在的替代方案。例如,海洋衍生的生物活性化合物已经获得了很多兴趣,因此被广泛利用以面临实践同行的范围,这对21世纪的医疗环境变得无效。利用天然可用的生物活性化合物及其衍生物可以使这些合成化合物的问题最小化以治疗RA。几种海洋衍生的化合物表现出抗炎和抗氧化性能,可以有效地用于对Ra的治疗目的。若干研究的结果确保了来自海洋来源的生物活性化合物的提取可以提供针对RA的新药发育的新和安全来源。最后,在本次审查中纳入了当前的挑战,差距和未来的观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号